Last updated July 22, 2026
Key finding
Among patients in the ertugliflozin and pioglitazone groups, 45% to 23.4% and 41.7% to 26.6%, respectively, decreased in the Grade 2 group.
This study evaluated the effects of ertugliflozin on liver function in patients with nonalcoholic fatty liver disease and type 2 diabetes, finding significant improvements in liver-related biomarkers.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of ertugliflozin on liver function in patients with nonalcoholic fatty liver disease and type 2 diabetes, finding significant improvements in liver-related biomarkers.
Improving liver function in patients with nonalcoholic fatty liver disease is crucial, as it can prevent progression to more severe liver conditions. The findings suggest that ertugliflozin may be an effective treatment option for managing liver health in individuals with type 2 diabetes, potentially leading to better overall health outcomes.
Limited sample size may affect generalizability. Short duration of the study may not capture long-term effects. Potential biases in self-reported outcomes.
Published in
Publication details and source links for this paper.
Adil K, Haroon B, Yasar S, et al. Ertugliflozin Improves Liver Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes. Medicine. 2024;103(45):e40356. doi:10.1097/MD.0000000000040356
Liver fat content decreased by -0.45 grade (P ≤ 0.001).
AST levels reduced by -53.3 IU/L (P ≤ 0.001).
ALT levels decreased by -52.2 IU/L (P ≤ 0.001).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Ertugliflozin and AST, Alanine Aminotransferase (ALT), Body weight, and 10 more.
This study contributes evidence to
Primary intervention
Ertugliflozin
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
13
Evidence pairs
487
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Ertugliflozin → Alanine Aminotransferase (ALT)
Ertugliflozin → Alanine Aminotransferase (ALT)
Ertugliflozin → Change in liver enzymes (GGT)
Ertugliflozin → Change in liver enzymes (GGT)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Ertugliflozin and HbA1c, Ertugliflozin and Uric Acid.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies on Ertugliflozin
Contributes to Ertugliflozin evidence base.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies measuring Uric Acid
Measures Uric Acid as a key outcome.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
2 results
2 results
2 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
Ertugliflozin may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Ertugliflozin may worsen Uric Acid or be associated with harm.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Uric Acid
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | weak negative | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Ertugliflozin appears to improve AST.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
AST
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Ertugliflozin appears to improve Alanine Aminotransferase (ALT).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Alanine Aminotransferase (ALT)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
